基于生物信息數(shù)據(jù)庫(kù)分析前列腺癌組織特異性lncRNA表達(dá)及臨床意義
Analysis of the expression and clinical significance of prostate cancer tissue,specific lncRNAs based on bioinformatics databases
CHEN Pingzhou1,XU Qingjiang1,LIN Huang1,HUANG Xiang2,WU Xiang1
(1.Department of Urology,F(xiàn)ujian Provincial Hospital,F(xiàn)uzhou 350004;2.Department of Urology,Nanping First Hospital Affiliated to Fujian Medical University,Nanping 353000,China)
ABSTRACT:ObjectiveTo explore the expression and clinical significance of prostate cancer tissue,specific lncRNAs. MethodsThe gene differences of 492 prostate cancer tissues and 152 adjacent tissues in TCGA and GEO genomic databases were analyzed with bioinformatics methods. A total of 5 lncRNAs were screened out,and their specificity in prostate tissues and impact on the prognosis of patients were analyzed. ResultsThe 5 lncRNAs included PCAT14,PCA3,CTBP1,AS,DRAIC,and GPC5,AS1. PCAT14 and PCA3 were specifically expressed in prostate cancer tissues,and elevated expression was related to the prognosis. Moreover,they were well correlated with prostate cancer,specific antigens such as KLK3,AMACR,SLC45A3,and so on. GO function enrichment analysis and KEGG pathway enrichment analysis showed that the differential expression of PCA3 was closely related to phagocytosis,cell recognition,defense response to bacteria,immunoglobulin complex,Golgi apparatus,antigen binding,chemokine receptor binding,white matter digestion and absorption,renin,angiotensin system and other signaling pathways,while the differential expression of PCAT14 was closely related to the activity of Golgi apparatus and ion channels,renin secretion,cAMP signaling pathway,and gonadotropin secretion,related signaling pathway.ConclusionPCA3 and PCAT14 are specifically expressed in prostate cancer tissues,not in normal tissues,which can be used as potential indicators for the diagnosis of prostate cancer.
KEY WORDS:prostate cancer;bioinformatics;lncRNA;PCAT14;PCA3
摘要:目的研究前列腺癌組織特異性長(zhǎng)鏈非編碼RNA(lncRNA)表達(dá)及其臨床意義。(剩余9223字)
-
-
- 現(xiàn)代泌尿外科雜志
- 2024年03期
- 改良(免port)機(jī)器人單孔前...
- 基于GSS算法的HRD評(píng)分與高...
- 高瘤負(fù)荷骨轉(zhuǎn)移前列腺癌患者列線...
- 基于68Ga,PSMA,11 ...
- 單一術(shù)者65例機(jī)器人輔助腹腔鏡...
- 基于TCGA數(shù)據(jù)庫(kù)分析lncR...
- 基于生物信息數(shù)據(jù)庫(kù)分析前列腺癌...
- 初始治療采用根治性切除術(shù)或近距...
- 經(jīng)腹膜外三孔法機(jī)器人輔助前列腺...
- CMTM6、RASAL2在前列...
- 酒精、咖啡、綠茶和乳制品的攝入...
- 核受體NURR1在前列腺癌細(xì)胞...
- 經(jīng)會(huì)陰穿刺注射玻璃酸鈉擴(kuò)張狄氏...
- 高分組前列腺癌組織中PCDH9...
- 前列腺靶向穿刺活檢新進(jìn)展...
- 免疫治療在前列腺癌中應(yīng)用的現(xiàn)狀...
- 睪丸軟斑癥1例報(bào)告...
- Birt,Hogg,Dub...